Dragbuterol®

Oral Gel.

Bronchodilator for horses.

Each 100 mL of gel contains:
Clenbuterol Hydrochloride………. 2.0 mg
Excipients c.s.p……………..…..100 mL

Horses.

Dragbuterol® is mainly indicated for the treatment of obstructive diseases of the respiratory tract in horses, such as chronic obstructive pulmonary disease and allergic respiratory diseases. It is also indicated for its mucolytic action as an adjuvant in the treatment of infectious respiratory diseases, such as pneumonia and bronchitis.

Orally.

Dose of the active ingredient:

• Initial dose: 0.8 μg of Clenbuterol Hydrochloride/Kg of b.w. every 12 hours.
  If after 3 days of treatment (6 doses) no improvement is observed, increase the dose according to the following scheme:
• 1.6 μg of Clenbuterol Hydrochloride/Kg of b.w. every 12 hours for 3 days, if there is no improvement,
• 2.4 μg of Clenbuterol Hydrochloride/Kg of b.w. every 12 hours for 3 days, if there is no improvement,
• 3.2 μg of Clenbuterol Hydrochloride/Kg of b.w. every 12 hours for 3 days.

Product dosage:

• Initial dose and mild obstructive symptoms: 4 mL/100 Kg of body weight, every 12 hours for 30 days.
• Severe broncho-obstructive symptoms: maximum dose of 12-16 mL/100 Kg of body weight. every 12 hours for 30 days.
  If after 3 days of treatment (6 doses) with the initial dose no improvement is observed, increase the dose according to the following scheme:
• 8 mL/100 Kg of body weight, every 12 hours for 3 days, if there is no improvement,
• 12 mL/100 Kg of body weight, every 12 hours for 3 days, if there is no improvement,
• 16 mL/100 Kg of b.w., every 12 hours for 3 days.
  Once the therapeutic dose is established, continue treatment for 30 days. If signs reappear, treatment can be repeated for an additional 30 days, but determination of the effective dose must be done again in stages.
  If after administering the higher dose no effect is observed, it means that the animal is not responding to Clenbuterol or that the obstructive condition is not of bronchial origin, then the treatment should be suspended.

• Do not administer to animals hypersensitive to Clenbuterol Hydrochloride.
• Do not administer to horses with cardiovascular disorders.
• Do not administer to mares in advanced pregnancy or lactation.
• Do not administer to breeding males.
• Do not administer to young.

Moderate tachycardia, sweating, muscle tremor, hives, and restlessness may occur during the first days of treatment. The presence of ataxia is also described, although in low frequency.

• Concomitant administration with other sympathomimetic amines (for example Terbutaline) may increase the adverse effects of Clenbuterol.
• Use with inhalation anesthetics (e.g. Halothane, Isoflurane) may predispose to ventricular arrhythmias, particularly in patients with pre-existing cardiac disease.
• Use with digitalis glycosides may increase the risk of cardiac arrhythmias.
• β-blockers (for example Propranolol) can antagonize the effects of Clenbuterol.
• Clenbuterol can antagonize the effects of Prostaglandin F2 and Oxytocin.

• It is not recommended to start treatment with a dose higher than the established initial dose.
• Keep out of reach of children.

• Do not handle by people hypersensitive to Clenbuterol Hydrochloride.
• Do not handle by pregnant women.

Do not administer to horses whose meat is intended for human consumption.

Empty containers can be discarded as household waste, without any special precautions. Do not dispose of containers with product remains on the ground or in water courses. For expired or unused products, contact the manufacturing laboratory.

Store between 15 and 30°C, protected from light. Once the container is opened, use within 3 days. Discard unused product after that period of time.

Sale under Veterinary Medical prescription withheld.

VETERINARY USE
ORAL USE

Reg. SAG N° 1866

Bottle with 50 mL

Laboratorio Drag Pharma Chile Invetec S.A.
Lautaro N° 300. Quilicura. Santiago. Chile.